Research
Hormonal
The EMPA-REG OUTCOME study demonstrated that a glucose-lowering agent lowered cardiovascular mortality and all-cause mortality.
This suggests that glucose-lowering agents may be beneficial for reducing mortality in high-risk T2DM patients.
StrongSupportsmedium confidence
This trial was the first dedicated CV outcomes study to demonstrate that a glucose-lowering agent lowered CV mortality and all-cause mortality.
Why this rating
Based on the results of a dedicated clinical trial.
Source
Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes
Helmut O. Steinberg · Postgraduate Medicine · 2016
DOI 10.1080/00325481.2016.1168687
reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →